Noncardiac pulmonary edema.

摘要: ARDS is a severe disorder affecting over 150,000 patients per year in the United States alone. The syndrome has multiple etiologies that to larger extent determine 60% 70% mortality associated with process. In spite of intense research, there still no specific therapy proven benefit we can offer patients. Supportive measures designed keep patient alive long enough allow pulmonary lesion heal are mainstay therapy. These constantly being improved and increasingly require invasive high technology. Even advances treating established ARDS, careful attention toward prevention day-to-day management will be required reduce excessive mortality.